ID: h-7eaed928c5
Hypothesis
TREM2 Microglial Activation Rescues Amyloid Clearance in AD
TREM2 agonistic antibodies restore microglial phagocytosis and plaque compaction in Alzheimer's disease, particularly for R47H variant carriers with ~3-fold increased AD risk.
EvidencePending (0%)📖 0 cit🗣 2 debates✓ 3 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
TREM2 agonistic antibodies restore microglial phagocytosis and plaque compaction in Alzheimer's disease, particularly for R47H variant carriers with ~3-fold increased AD risk. Multiple agonistic antibodies (AL002c, 4D9) are in development targeting the SYK/PLCγ2/CARD9 cascade. Critical uncertainties include biphasic dose-response pharmacology, appropriate mouse model design (conditional knockout rather than constitutive knockout), and the temporal window for therapeutic intervention given biphasic CSF sTREM2 patterns in AD patients.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["TREM2 Activation<br/>Microglial Receptor"]
B["Amyloid Plaque<br/>Phagocytosis"]
C["Homeostatic to DAM<br/>Microglia Transition"]
D["Lysosomal<br/>Biomolecule Processing"]
E["Neuroinflammatory<br/>Resolution"]
F["Synaptic<br/>Protection"]
G["Cognitive<br/>Preservation"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix3 supports3 contradicts
Contradicts
CSF sTREM2 shows biphasic temporal pattern in AD—elevated early, suppressed late
Contradicts
High TREM2 agonist concentrations cause receptor internalization and desensitization
📖 Linked Papers (4)Export BibTeX ↗
Synergistic potential of TREM2 agonists and exercise training in Alzheimer's disease.
Am J Physiol Endocrinol Metab (2026) · PubMed:41494649 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Interplay between CD33 and TREM2 in Alzheimer's Disease: Potential Mechanistic Insights into Microglial Function in Amyloid Pathology.
ACS chemical neuroscience (2026) · PubMed:41388352 ↗
No figures
Microglial mTOR Activation Upregulates Trem2 and Enhances β-Amyloid Plaque Clearance in the
The Journal of neuroscience : the official journal of the Society for Neuroscience (2022) · PubMed:35672148 ↗
No figures
🏥 Translation
🧬 3D Protein Structure — TREM2
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for TREM2 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 2.3%
Volatility
High
0.0944
Events (7d)
3
Price History
▼18.8%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF heterozygous R47H TREM2 variant carriers with early-stage Alzheimer's disease (MMSE 20-26) receive 12 months of subcutaneous TREM2 agonistic antibody (AL002c at 5mg/kg biweekly) THEN their CSF Aβ42 | Mean increase in CSF Aβ42/40 ratio of ≥15% from baseline in the treatment arm, with statistical significance (p<0.05) versus placebo. | — no observation — | pending | 0.45 |
| IF aged 18-month 5xFAD mice with conditional TREM2 deletion (Trem2-flox/Cre-ERT2, not constitutive KO) receive intraperitoneal 4D9 antibody at 3mg/kg twice weekly for 8 weeks THEN microglial plaque co | Mean microglial plaque coverage increase of ≥40% in TREM2-agonist-treated conditional KO mice versus vehicle controls, with reduced plaque diameter and increase | — no observation — | pending | 0.52 |
🔮 Falsifiable Predictions (2)
pendingconf 52%
IF aged 18-month 5xFAD mice with conditional TREM2 deletion (Trem2-flox/Cre-ERT2, not constitutive KO) receive intraperitoneal 4D9 antibody at 3mg/kg twice weekly for 8 weeks THEN microglial plaque coverage (Iba1+ area colocalized with 6E10+ plaques) will increase by ≥40% compared to vehicle-treated
Predicted outcome: Mean microglial plaque coverage increase of ≥40% in TREM2-agonist-treated conditional KO mice versus vehicle controls, with reduced plaque diameter an
Falsification: Microglial plaque coverage shows no significant increase (<15%) or actual decrease in TREM2-agonist-treated conditional KO mice compared to vehicle, or no difference between conditional KO and WT mice
pendingconf 45%
IF heterozygous R47H TREM2 variant carriers with early-stage Alzheimer's disease (MMSE 20-26) receive 12 months of subcutaneous TREM2 agonistic antibody (AL002c at 5mg/kg biweekly) THEN their CSF Aβ42/40 ratio will increase by ≥15% from baseline (indicating reduced amyloid burden) compared to age-ma
Predicted outcome: Mean increase in CSF Aβ42/40 ratio of ≥15% from baseline in the treatment arm, with statistical significance (p<0.05) versus placebo.
Falsification: CSF Aβ42/40 ratio shows no significant change (difference <5%) or decreases in R47H carriers receiving TREM2 agonist compared to placebo after 12 months.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.